Gene deficiency or pharmacological inhibition of PDCD4-mediated FGR signaling protects against acute kidney injury

• Published in: Acta pharmaceutica Sinica. B 2021-02, Vol.11 (2), p.394-405
• Main Authors: Jing, Xu, Ren, Dandan, Gao, Fei, Chen, Ye, Wu, Xiao, Han, Yue, Han, Qingsheng, Li, Liang, Wang, Xiaojie, Tang, Wei, Zhang, Yan
• Format: Article
• Language: English
• Subjects: Acute kidney injury; Cell death; FGR; Inflammation; Ischemia–reperfusion injury; NOTCH1; Original; PDCD4; Tyrosine kinase
• ISSN: 2211-3835; 2211-3843
• DOI: 10.1016/j.apsb.2020.10.024

Recent studies have shown that programmed cell death 4 (PDCD4) modulates distinct signal transduction pathways in different pathological conditions. Despite acute and chronic immune responses elicited by ischemia contributing to the functional deterioration of the kidney, the contributions and mechanisms of PDCD4 in acute kidney injury (AKI) have remained unclear. Using two murine AKI models including renal ischemia/reperfusion injury (IRI) and cisplatin-induced AKI, we found that PDCD4 deficiency markedly ameliorated renal dysfunction and inflammatory responses in AKI mice. Consistently, upregulation of PDCD4 was also confirmed in the kidneys from patients with biopsy confirmed acute tubular necrosis from a retrospective cohort study. Moreover, we found that overexpression of Fgr, a member of the tyrosine kinase family, dramatically aggravated renal injury and counteracted the protective effects of PDCD4 deficiency in AKI mice. We discovered that FGR upregulated NOTCH1 expression through activating STAT3. Most importantly, we further found that systemic administration of ponatinib, a tyrosine kinase inhibitor, significantly ameliorated AKI in mice. In summary, we identified that PDCD4 served as an important regulator, at least in part, of FGR/NOTCH1-mediated tubular apoptosis and inflammation in AKI mice. Furthermore, our findings suggest that ponatinib-mediated pharmacologic targeting of this pathway had therapeutic potential for mitigating AKI. Programmed cell death 4 (PDCD4) contributes to inflammation and promotes tubular epithelial cell death in acute kidney injury (AKI), which is associated with the FGR-mediated NOTCH1 signaling pathway. Using ponatinib or other drugs targeting this pathway may represent novel therapeutic strategies for the treatment of AKI. [Display omitted]